Two Stocks Under Discussion: Funko, Inc. (NASDAQ:FNKO), Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)

Funko, Inc. (NASDAQ:FNKO)

Funko, Inc. (NASDAQ:FNKO) closed at $21.83 on the last trading session with an increase of 0%, whereas, it previously closed at $21.83. The company has a market capitalization of $1.02 Billion. The company traded shares of 0 on the trading day while its three month average volume stands at 615.28 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Funko, Inc. (NASDAQ:FNKO) produced diluted EPS of 0.45. The EPS estimate for next year as estimated by analysts is at 1.38 while EPS for next quarter is estimated at 0.13. Earnings per Share growth for this year is reported at 112.4, while the analysts estimated the EPS growth for next year at 1.38% and Earnings growth for next 5 years stands at 1.8% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 0%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Funko, Inc. (NASDAQ:FNKO) is at 48.95 while the forward p/e is at 15.86. The P/S or Price to Sales ratio of Funko, Inc. (NASDAQ:FNKO) stands at 1.43 and Price to Book or P/B for the most recent quarter stands at 3.25. The Price to Free Cash Flow ratio or P/FCF is reported at 23.71. The quick ratio and the current ratio of Funko, Inc. (NASDAQ:FNKO) are reported at 1.3 and 1.9 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Funko, Inc. (NASDAQ:FNKO) stands at 1.6, 6.9 and 13.4 respectively

The trailing twelve month Revenue of Funko, Inc. (NASDAQ:FNKO) is reported at 715.7 Million with income of 10.6 Million. The outstanding shares of Funko, Inc. (NASDAQ:FNKO) are 46.93 Million. The institutional Ownership of the shares of 75 stands at 0.80%, this figure is increased 7.47 in the last six months. The insider ownership for the shares of Funko, Inc. (NASDAQ:FNKO) is ticked at 10.6%, the figure is rose 0% in the last six months.

Some other important financial aspects to be discussed here for Funko, Inc. (NASDAQ:FNKO) is the Mean Target Price estimated by the analysts which stands at 25.14. The 52 week high of Funko, Inc. (NASDAQ:FNKO) is placed at 31.12 and 52 week low is standing at 11.03.

Performance wise the shares of Funko, Inc. (NASDAQ:FNKO) rose up 5.26% for the week, it also rise 2.58% for the monthly performance, while for the quarter it went down 3.46%. The shares increase 55.48% for the half year and flew up for the Year-To-Date performance. The shares of Funko, Inc. (NASDAQ:FNKO) grew 84.06% for the yearly performance.

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) closed at $4.23 on the last trading session with an increase of 0%, whereas, it previously closed at $4.23. The company has a market capitalization of $347.49 Million. The company traded shares of 0 on the trading day while its three month average volume stands at 1.04 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) produced diluted EPS of -0.9. The EPS estimate for next year as estimated by analysts is at -0.06 while EPS for next quarter is estimated at -0.19. Earnings per Share growth for this year is reported at -11.6, while the analysts estimated the EPS growth for next year at -0.06% and Earnings growth for next 5 years stands at 0% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at -2.6%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) is at 0 while the forward p/e is at 0. The P/S or Price to Sales ratio of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) stands at 20.81 and Price to Book or P/B for the most recent quarter stands at 4.27. The Price to Free Cash Flow ratio or P/FCF is reported at 0. The quick ratio and the current ratio of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) are reported at 4.8 and 4.8 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) stands at -44.3, -80.6 and -44.4 respectively

The trailing twelve month Revenue of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) is reported at 16.7 Million with income of -73000000. The outstanding shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) are 82.15 Million. The institutional Ownership of the shares of 78.1 stands at 0.80%, this figure is decreased -7.89 in the last six months. The insider ownership for the shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) is ticked at 6.46%, the figure is rose 0% in the last six months.

Some other important financial aspects to be discussed here for Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) is the Mean Target Price estimated by the analysts which stands at 9.92. The 52 week high of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) is placed at 9.42 and 52 week low is standing at 3.62.

Performance wise the shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) rose up 2.17% for the week, it also fell -11.32% for the monthly performance, while for the quarter it went up -4.3%. The shares decrease -10% for the half year and flew up for the Year-To-Date performance. The shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) shrinked -51.93% for the yearly performance.